Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreightons Regulatory News (CRL)

Share Price Information for Creightons (CRL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 25.00
Bid: 23.00
Ask: 27.00
Change: 0.00 (0.00%)
Spread: 4.00 (17.391%)
Open: 25.00
High: 25.00
Low: 25.00
Prev. Close: 25.00
CRL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of Emma Hardie Limited and TVR

29 Jul 2021 07:00

RNS Number : 8331G
Creightons PLC
29 July 2021
 

For immediate release 29 July 2021

 

CREIGHTONS plc ("Creightons" or the "Company")

Acquisition of Emma Hardie Limited

and

Total Voting Rights

Acquisition of Emma Hardie Limited

Creightons plc (LSE: CRL), manufacturers of personal care, beauty, and fragrance products, announces that it has acquired the entire share capital of Emma Hardie Limited including the Emma Hardie skincare brand.

Emma Hardie Limited sells products under the Emma Hardie Skincare brand and prides itself on creating natural, cruelty-free, innovative products. Founded in September 2009, Emma Hardie Skincare has become an international, independent skincare brand with over 40 prestigious beauty awards with customers throughout the UK, Europe, USA, and Asia Pacific.

The consideration for the transaction is approximately £6.36 million, comprising £5 million in cash and the issue of 1,600,000 ordinary shares of 1p each in the Company ("New Ordinary Shares") at the volume weighted average middle market CRL quoted price for preceding 5 Business Days of 84.78 per share ("Consideration Shares").

If on the date of twelve months from completion the volume weighted average middle market quoted price of an Ordinary Share for the last 5 Business days prior to that date (as derived from the Daily Official List of London Stock Exchange Plc) is less than £1.25, then an additional amount shall be payable to the sellers in cash equal to such difference in price multiplied by the number of Consideration Shares issued. The Consideration Shares will be subject to a lock-in mechanism for twelve months.

Application will be made by the Company to the Financial Conduct Authority and to the London Stock Exchange for the New Ordinary Shares to be admitted to the Official List and to trading on the London Stock Exchange's main market for listed securities ("Admission"). It is expected that Admission will become effective and dealings will commence on or around 4 August 2021.

The gross assets of Emma Hardie Limited as recorded in the most recent available accounts to 30 June 2020 were £2,463,895. The profits before tax of Emma Hardie Limited for the year ended 30 June 2020 were £46,819. The turnover was £3,834,771.

The acquisition represents an important development for Creightons plc with the addition of a premium skincare brand with an established consumer base. The addition of a premium skincare brand strengthens our brand portfolio and offering by taking the business into a higher end group of retailers and digital platforms. There are both manufacturing and management synergies that will drive a higher return in the brand, as well as significant opportunities for extending the distribution of the brand in the UK market and in multiple international markets. Our in-house development and brand teams will also be able to extend the bandwidth of the brand offering, to drive sales expansion and margin opportunities.

Creightons plc has retained the services of Barry Cook, former Managing Director of Emma Hardie Limited in order to facilitate a smooth transition and to develop new sales opportunities. 

Mr Bernard Johnson Managing Director of the Company commented: 'We are pleased to announce the acquisition of Emma Hardie Limited which represents a significant investment is a premium skincare business with an impressive digital customer base. It is consistent with our strategy to develop our branded business which we have identified as a key driver for growth in the future.'

Total Voting Rights

On Admission, the number of shares in issue will be 66,452,243 ordinary shares of 1p each and therefore, the total number of voting rights in the Company will be 66,452,243.

The above statement of voting capital may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Enquiries - Analysts and Investors:

Nicholas O'Shea, Director, Creightons Plc 01733 281000

Roland Cornish / Felicity Geidt, Beaumont Cornish Limited 0207 628 3396

Press Nigel Szembel, Anagallis Communications Limited 07802 362088 nigelszembel@anagallis.co.uk

 

Authorised for immediate release

 

ND O'SheaDirector28/07/2021

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDGGDRIXDDGBI
Date   Source Headline
15th Mar 202410:52 amRNSBlock listing Interim Review
7th Mar 20247:00 amRNSDirectorate Change
4th Dec 20237:00 amRNSHalf-year Report
27th Nov 20237:00 amRNSDirectorate Change
25th Sep 202311:50 amRNSDirector/PDMR Shareholding
15th Sep 20235:24 pmRNSBlock listing Interim Review
14th Sep 20239:52 amRNSResult of AGM
1st Sep 20235:17 pmRNSDirector/PDMR Shareholding
1st Sep 20235:05 pmRNSDirector/PDMR Shareholding
25th Aug 20233:32 pmRNSDirector/PDMR Shareholding
31st Jul 20232:53 pmRNSReplacement: Director/PDMR Shareholding
24th Jul 202311:54 amRNSDirector/PDMR Shareholding
7th Jul 20237:00 amRNSAudited preliminary results
31st Mar 202310:49 amRNSTotal Voting Rights
17th Mar 20237:00 amRNSBlock listing Interim Review
16th Mar 20234:35 pmRNSPrice Monitoring Extension
27th Jan 20232:05 pmRNSSecond Price Monitoring Extn
27th Jan 20232:00 pmRNSPrice Monitoring Extension
12th Jan 20232:05 pmRNSSecond Price Monitoring Extn
12th Jan 20232:00 pmRNSPrice Monitoring Extension
30th Dec 202211:05 amRNSSecond Price Monitoring Extn
30th Dec 202211:00 amRNSPrice Monitoring Extension
20th Dec 20224:40 pmRNSSecond Price Monitoring Extn
20th Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSHalf-year Report
29th Nov 20224:41 pmRNSSecond Price Monitoring Extn
29th Nov 20224:36 pmRNSPrice Monitoring Extension
25th Nov 20227:00 amRNSInterim Results 2022 - announcement, presentations
27th Sep 20227:00 amRNSUpdate on Emma Hardie, Trading in own shares & TVR
20th Sep 20229:22 amRNSBlock Listing Update
24th Aug 20221:01 pmRNSResult of AGM
12th Jul 20229:05 amRNSSecond Price Monitoring Extn
12th Jul 20229:00 amRNSPrice Monitoring Extension
12th Jul 20227:00 amRNSResults for year to end 31 March 2022
11th Jul 20227:00 amRNSPreliminary Results, investor/analyst presentation
4th Jul 20224:42 pmRNSTotal Voting Rights
7th Jun 20223:28 pmRNSTotal Voting Rights
3rd May 20226:09 pmRNSTotal Voting Rights
12th Apr 20224:33 pmRNSDirector/PDMR Dealing, Total Voting Rights
21st Mar 202211:37 amRNSBlock listing Interim Review
7th Mar 20229:59 amRNSTotal Voting Rights
14th Jan 20222:58 pmRNSTotal Voting Rights
30th Dec 20217:00 amRNSHalf-year Report
15th Dec 20212:52 pmRNSNotice of Interim Results & Investors Presentation
6th Dec 20215:38 pmRNSTotal Voting Rights
25th Nov 20216:18 pmRNSDirector/PDMR Shareholding and Total Voting Rights
23rd Nov 20214:49 pmRNSDirector/PDMR Shareholding
18th Nov 202111:55 amRNSDirector/PDMR Shareholding
17th Nov 20211:58 pmRNSDirector/PDMR Shareholding
15th Nov 20217:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.